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Edited by Lukas HuberAbstract Tumour necrosis factor receptor-associated periodic
syndrome (TRAPS) results from point mutations in the extracel-
lular domain of TNF receptor 1 (TNFRSF1A), but the eﬀects of
the mutations are controversial. This study shows that reduced
NF-jB signalling is a feature of four TRAPS mutations. Re-
duced signalling correlates with reduced surface expression, mea-
sured by ﬂow cytometry and microscopy. This suggests that
correct formation of the extracellular domain of TNFRSF1A
is important for localisation and receptor function. Importantly,
our data provides a mechanism for the reduced TNFRSF1 sig-
nalling observed in a patient cell line.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumour necrosis factor receptor-associated periodic syn-
drome (TRAPS; MIM 142680) is an autoinﬂammatory syn-
drome, characterised by recurrent fevers with cutaneous,
muscle and joint inﬂammation, associated with autosomal
dominantly-inherited mutations in the gene that encodes
tumour necrosis factor (TNF) receptor superfamily 1A
(TNFRSF1A) [1]. TNFa exerts its many pro-inﬂammatory
eﬀects through two distinct receptors: TNFRSF1A (TNFR1,
p55/p60-TNFR) and TNFRSF1B (TNFR2, p75/p80-TNFR).
TNFRSF1A is widely expressed and appears to be the major
receptor for soluble TNFa-induced signaling [2]. At least 60
TNFRSF1A mutations associated with TRAPS have been re-
ported on the INFEVERS (Internet periodic fevers) website
(http://fmf.igh.cnrs.fr/infevers/). The majority are located in
the ﬁrst or second cysteine-rich extracellular domains (CRD1
and CRD2). The binding site for TNFa is formed by CRD2
and CRD3 of TNFRSF1A [3], while CRD1, also known as
the pre-ligand assembly binding domain, is thought to mediate
TNFRSF1A self-assembly [4].
The initial study of TRAPS suggested that the TNFRSF1A
mutations impair activation-induced shedding of the receptorAbbreviations: TRAPS, tumour necrosis factor receptor-associated
periodic syndrome; TNFa, tumour necrosis factor alpha; TNFRSF,
TNF receptor superfamily; CRD, cysteine-rich domain
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doi:10.1016/j.febslet.2005.08.037[1]. However, this is not the case for all mutations [5,6] and var-
ies according to cell type [7]. Another study has shown that
overexpression of TRAPS-associated TNFRSF1A mutants
spontaneously induce apoptosis and interleukin-8 production
although TNFa binding to the mutated receptors appears to
be defective [8].We have recently shown that cells from a patient
with TRAPS, bearing the C43S mutation, have decreased
NF-jB induction and TNFa-induced apoptosis, although
IL-6 and IL-8 production were normal [6] suggesting that
reduced TNFRSF1A signalling may be a feature of TRAPS.
This study was initiated to investigate whether reduced
TNFRSF1A signalling was a general feature of TRAPS muta-
tions. We transfected cells with either wild-type (WT) or the
following mutant recombinant forms of TNFRSF1A: C30R,
C43S, T50M and C52F. We investigated the eﬀects of these
clinically relevant mutations on receptor function, in terms
of NF-jB activation, on cell death and on receptor expression.
Our work shows that all of these TRAPS mutations result in
decreased TNFRSF1A signalling and that this loss of signal-
ling correlates with reduced expression of the receptor on the
surface of cells.2. Materials and methods
2.1. Production of recombinant TNFRSF1A DNA clones and plasmids
The TNFRSF1A coding region was ligated into the pcDNA3.1 myc/
His B vector (Clontech). The TRAPS mutations were generated using
the Quikchange site-directed mutagenesis kit (Stratagene). Primers
used: C30R: 5 0-CGATTTGCCGTACCAAGTGCCAC-3 0, C43S:
5 0-CTTGTACAATGACTCTCCAGGCCCGGGGC-30, T50M 5 0-CC-
GGGGCAGGATATGGACTGCAGGGAG-30, C52F: 5 0-GGCAG-
GATACGGACTTCAGGGAGTGTG AGAG-30 and their reverse
complements. Mutations were conﬁrmed by sequencing. The 3Enh.jB-
ConALuc reporter (3EnhLuc) contains three NF-jB binding [9].2.2. Cells, transfection, luciferase reporter assay and cell viability assay
Eli-BL and DG75 B-cell lymphoma culture has been described [10].
107 cells in 0.5 ml culture medium with 100 mMHEPES (pH 7.2), were
transfected using a Biorad Genepulser II (270 V/950 lF). Transfection
eﬃciency was typically 5–20% for the Eli-BL and 40–50% for the
DG75. Luciferase assays were performed in the transfected Eli-BL
cells. Cells were stimulated after 16 h. Luciferase activity was measured
8 h later [11]. Transfection eﬃciency was assessed using the Promega
Dual-Luciferase reporter system.
Cell viability was assessed by alamar blue assay (Biosource). Brieﬂy,
2 · 104 transfected cells were resuspended in 200 ll of 10% alamar blue
reagent in growth medium on a 96 well plate. After 4 h incubation at
37 C, readings were made on a FLUOstar Optima (BMG Laborato-
ries) using the ﬂuorescence conﬁguration.blished by Elsevier B.V. All rights reserved.
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immunoﬂuorescence
For surface expression, cells were harvested 24 h after transfection,
washed with phosphate buﬀered saline (PBS) and ﬁxed in 2% parafor-
maldehyde. Cells were washed and resuspended in 10% normal rabbit
serum (NRS) in PBS for 20 min. Cells were stained with anti-
TNFRSF1A monoclonal antibody (Ab-1, Calbiochem) followed by
an anti-mouse R-phycoerytherin (RPE)-conjugated F(ab 0)2 fragment
(Dako), or with mouse IgG1-conjugated PE negative control (Serotec).
Washed cells were resuspended in 2% paraformaldehyde and analysed
using a Becton Dickinson FACScalibur. Total (surface and intracellu-
lar) expression of TNFRSF1A was assayed following permeabilisation
with 0.1% Triton X-100/PBS after ﬁxation and stained as before.
For confocal microscopy, cells were washed, ﬁxed with 2% parafor-
maldehyde, resuspended in PBS and air-dried. Cells were permeabi-
lised with 0.1% Triton X-100/PBS, incubated in 10% NRS/PBS and
stained with the same anti-TNFRSF1A antibody followed by an Alexa
Fluor 488 anti-mouse IgG antibody (excited 488 nm – detected
520 nm). For nuclear staining, cells were incubated with DRAQ5
10 lM (Biostatus) for 10 min (excited 647 nm – detected 680/30 nm).
Images were acquired using a confocal laser scanning microscope (Bio-
rad), with a krypton/argon ion laser and a Zeiss Axiovert 135. Results
are representative of ﬁve experiments.3. Results
3.1. The TNFRSF1A mutants result in reduced NF-jB activity
NF-jB is a critical transcription factor for the induction of
inﬂammation by TNFa [12]. NF-jB activation by wild-type
and mutant recombinant forms of TNFRSF1A was assessed0
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Fig. 1. NF-jB activation by WT and mutant recombinant forms of TNFR
reporter (3 lg) and TNFRSF1A constructs. Total DNA was constant at 23 lg
one half was stimulated with TNFa (10 ng/ml). After 8 h, luciferase activity w
stimulated cells. (C) TNFa dose response for cells transfected with TNF
experiments. Asterisks (*) indicate P < 0.05 between WT and the TRAPS con
jB ﬁreﬂy luciferase reporter (3 lg), a Renilla luciferase reporter (1 lg) and
Luciferase activities were measured after 8 h of TNFa (10 ng/ml) stimulationby luciferase reporter assay in transiently transfected Eli-BL
cells. Eli-BL cells express undetectable levels of membrane
TNFRSF1A by ﬂow cytometry and have low endogenous re-
sponses to TNFa [10], allowing measurement of alterations
in NF-jB activity as a result of transfection with recombinant
TNFRSF1A. Eli-BL cells were co-transfected with the NF-jB
luciferase reporter plasmid and either empty mammalian vec-
tor, mammalian expression vectors for wild-type TNFRSF1A
or a TNFRSF1A mutant. The mutants used were C30R, C43S,
T50M and C52F. C43S was the TRAPS mutation identiﬁed
and described by us previously [6]. C30R is the cysteine on
the opposite side of the disulﬁde bond to C43S. C52F was
one of the ﬁrst mutants described, and as there may be diﬀer-
ences between cysteine and non-cysteine mutations, we chose a
close by non-cysteine mutation, T50M.
Overexpression of TNFRSF1A resulted in increased NF-jB
activity, which was dependent on the amount of DNA trans-
fected (Fig. 1A). Interestingly, the level of NF-jB activation
was consistently, and signiﬁcantly, higher for WT TNFRSF1A
than for any of the four TRAPS mutants. In addition, there
appear to be diﬀerences in NF-jB activity between these
TRAPS mutants themselves, with the C30R mutation display-
ing minimal NF-jB activation. The diﬀerences in NF-jB activ-
ity between wild-type and the TRAPS mutants were more
pronounced in cells stimulated with TNFa (Fig. 1B). To inves-
tigate whether the TRAPS mutations had a diﬀerent dose re-
sponse curve, wild-type receptor and two of the TRAPS0
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tions. Reduced NF-jB was seen with the TRAPS mutants over
the full range of TNFa doses (Fig. 1C). Transfection eﬃciency
was assessed by dual luciferase assays. Cells were transfected
with the NF-jB reporter, expressing ﬁreﬂy luciferase, and an
SV40 promoter driving Renilla luciferase. Fig. 1D shows data
with normalised NF-jB activity for WT TNFRSF1A and two
TRAPS mutants. Both mutants show reduced NF-jB activity
even when normalised for transfection eﬃciency.0
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DNA (µg)3.2. Overexpression of the TRAPS mutants result in less cell
death than WT TNFRSF1A
As overexpression of TNFRSF1A itself can result in sponta-
neous cell death [8,13], cell viability assays were performed on
the transfected cells used for the luciferase assays. Alamar blue,
a non-toxic dye that is chemically reduced by the innate meta-
bolic activity of cells, was used to quantify cell viability [14]. Cell
viability was consistently lower in the Eli-BL cells transfected
with WT TNFRSF1A than those transfected with the mutant
forms of TNFRSF1A (Fig. 2A). The degree of cell death was
dependent on the amount of TNFRSF1A DNA transfected
but was independent of the TNFa dose (Fig. 2B). The decreased
cell death seen with the mutant recombinant forms of
TNFRSF1Ademonstrates that the reducedNF-jBactivity seen
with thesemutants is not as a result of diﬀerences in cell death. In
fact,when the percentage of viable cells is taken into account, the
diﬀerence in NF-jB activity between WT TNFRSF1A and the
TRAPS mutants increases further (Fig. 2C).0
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Fig. 2. Cell viability of the TNFRSF1A constructs. Cell viability was
tested, 16 h post-transfection with TNFRSF1A constructs (10 lg), in
untreated (A) and TNFa treated (B) in Eli-BL cells. The results are
shown relative to cells transfected with empty pcDNA3.1, expressed as
a percentage. Results are the means ± S.E.M. of three experiments.
* = P < 0.05 versus TRAPS constructs, by Students t-test. (C) NF-jB
activation by TNFRSF1A constructs adjusted for cell viability. NF-jB
activity, measured by luciferase assay, was divided by the percentage of
viable cells. All results shown are the means ± S.E.M. of three
experiments.3.3. The TRAPS mutations restrict cell surface expression of
TNFRSF1A
TNFRSF1A expression is a highly regulated process [15–17].
We analysed the cell surface expression of each of the four
TRAPS mutants to investigate whether diﬀerences in cell sur-
face expression were responsible for the reduced NF-jB activ-
ity and cell death. The highly transfectable DG75 B-cell line
was used as this allowed more sensitive analysis of
TNFRSF1A expression than the Eli-BL cell line. The DG75
cell line was unsuitable for the signaling assays as it has high
levels of constitutive NF-jB activity. While WT TNFRSF1A
could be detected easily on the surface of cells transfected with
this construct, surface expression of the TRAPS mutants re-
mained consistently low, with very little increase above basal
levels (Fig. 3A, white bars), even when the cells were transfec-
ted with 20 lg of plasmid. The alamar blue viability assays
indicate that there was signiﬁcantly more cell death in the cells
transfected with WT TNFRSF1A than in those transfected
with the mutant recombinant forms of TNFRSF1A. The lack
of surface expression of the TRAPS mutants cannot therefore
be attributed to increased cell death. In order to determine the
extent of intracellular expression of the TRAPS mutants,
transfected cells were permeabilised with 0.1% Triton X-100
prior to staining with anti-TNFRSF1A mAb. This was per-
formed in parallel with staining of unpermeabilised transfected
cells, allowing comparison of surface and cytoplasmic
TNFRSF1A levels. Following permeabilisation, cells transfec-
ted with WT TNFRSF1A showed enhanced staining, indicat-
ing detection of both surface and intracellular TNFRSF1A
(Fig. 3A, grey bars). Despite the lack of surface expression
of the TRAPS mutants, all four mutants were detected follow-
ing permeabilisation. Thus, these mutant recombinant formsof TNFRSF1A appear to be localised intracellularly, in con-
trast to the surface expression of WT TNFRSF1A.
The distribution of WT and mutant forms of TNFRSF1A
was further characterised by confocal microscopy. Transfec-
ted DG75 cells were permeabilised and then stained with
anti-human TNFRSF1A mAb and Alexa Fluor 488 second-
ary antibody, prior to detection by confocal microscopy.
The results conﬁrm that the TRAPS mutants diﬀer in their
localisation from WT TNFRSF1A (Fig. 3B). As expected,
WT TNFRSF1A was detected both on the surface of cells,
with a punctate staining pattern consistent with lipid raft dis-
tribution [17], and intracellularly. In contrast, the TRAPS mu-
tants were detected predominantly intracellularly. These
Fig. 3. Expression of TNFRSF1A mutants in transfected DG75 cells. (A) DG75 cells were transfected with 2 lg of EGFP-N1 and 10 lg of empty
pcDNA3.1 vector or one of the TNFRSF1A expression vectors. Cells were stained, as described, either without permeabilisation, for surface
staining, or following permeabilisation with 0.1% Triton X-100, for intracellular and surface expression. Results shown are the average (±S.E.M.)
mean ﬂuorescence intensity (m.f.i.) of transfected (GFP positive) cells. WT TNFRSF1A transfected cells were also stained with an isotype IgG1
antibody as a control (m.f.i. 7 ± 1). (B) DG75 cells were transiently transfected with WT or mutant TNFRSF1A. TNFRSF1A expression (green) was
analysed using a confocal microscope as described. Nuclei were stained with DRAQ5 (blue).
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ﬂow cytometry.
3.4. Removal of the intracellular domain does not restore the
surface expression of TRAPS mutants
Various portions of the intracellular domain of TNFRSF1A
have been shown to alter cellular localisation of the receptor
[10,15,17]. In particular, deletion of the death domain results
in increased, uniform surface expression of TNFRSF1A [17].
To test whether deletion of the intracytoplasmic domain re-
stores the surface expression of the mutated recombinant
forms of TNFRSF1A, truncated forms of the C43S
(C43SD218) and T50M (T50MD218) mutants were generated.
Removal of the intracytoplasmic domain (WTD218,
C43SD218, T50MD218) resulted in lack of NF-jB activation
(not shown). The WTD218 construct demonstrated markedly
increased surface expression by ﬂow cytometry (Fig. 4A) and
a uniform staining pattern on confocal microscopy (Fig. 4B).
In contrast, the truncated TRAPS mutants had low levels of
surface expression and a predominantly cytoplasmic staining
pattern, similar to that seen with the full-length TRAPS mu-
tants (Fig. 4A and B). Thus, removal of the intracytoplasmicportions of TNFRSF1A cannot rescue the reduced expression
of the receptor caused by the TRAPS mutations.
3.5. Co-transfection of WT and the C43S TRAPS mutant
results in reduction of NF-jB activity compared to
transfection of WT alone
As TRAPS has an autosomal dominant inheritance pat-
tern, the cells of patients with TRAPS will contain both
WT and mutated TNFRSF1A, which can potentially interact
although it is currently unknown whether this occurs. In
order to determine the eﬀects on NF-jB activation of the
TRAPS mutations in the presence of WT TNFRSF1A, lucif-
erase assays were performed in Eli-BL cells co-transfected
with both full-length WT and C43S. Co-transfection of WT
and C43S resulted in a level of NF-jB activation intermedi-
ate between that seen with either construct alone (Fig. 5).
Co-transfection with 2.5 lg of each WT and C43S resulted
in signiﬁcantly less NF-jB activation than either 2.5 or
5 lg of WT alone. These results are consistent with the re-
duced NF-jB activation previously demonstrated in a pri-
mary ﬁbroblast line established from a TRAPS patient with
the C43S mutation [6].
Fig. 4. Expression of full-length and truncated recombinant forms of
TNFRSF1A. Truncated forms (D218) have had the intracellular
domain of the receptor deleted. DG75 cells were transiently transfected
with 10 lg of either full-length or truncated forms of WT (WTD218),
C43S (C43SD218) and T50M (T50MD218). Cells were prepared as for
Fig. 3 and analysed by ﬂow cytometry (A) and confocal microscopy (B).
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Fig. 5. NF-jB activation following co-transfection of WT and the
C43S TRAPS mutant. Eli-BL cells were transiently transfected with
3 lg of NF-jB luciferase reporter and TNFRSF1A constructs. Total
DNA amount added to luciferase reporter was kept at 10 lg by the
addition of pcDNA3.1. Transfections were split into two, and 16 h
post-transfection, one half was stimulated with TNFa (10 ng/ml).
After 8 h, luciferase activity was assayed. The results shown are the
means ± S.E.M. of three experiments. *, P < 0.05 by Students t-test.
S. Siebert et al. / FEBS Letters 579 (2005) 5193–5198 51974. Discussion
This study demonstrates, for the ﬁrst time, that four diﬀerent
TRAPS mutations, C30R, C43S, T50M and C52F, have de-
creased NF-jB activity relative to WT TNFRSF1A. The re-
duced signalling correlates with reduced surface expression of
each of the four mutants. Importantly, the reductions in NF-
jB activity are consistent with our recent report demonstrating
that the C43S TRAPS mutation results in decreased NF-jB
activation in a patient-derived dermal ﬁbroblast line [6]. Fur-
thermore, this study shows that reduced TNFRSF1A signal-
ling is not just a feature of the C43S TRAPS mutation but
also of at least three other mutations. As TRAPS has an
autosomal dominant pattern of inheritance, patients cells
will express both WT and mutated TNFRSF1A. The co-
transfection of WT and mutant TNFRSF1A showed reduced
NF-jB activity compared to equivalent amounts of the WT
receptor expressed in isolation. This study is important as it
suggests that altered TNFRSF1A cell localisation may be a
mechanism for the reduced NF-jB signalling, and that this
mechanism may have relevance in vivo.
The cytoplasmic localisation and reduced cell surface expres-
sion of the TNRFR1 mutants seen in this study agrees with a
previous study using HEK-293 cells [8]. However, they showed
spontaneous apoptosis and cytokine production suggesting no
abrogation of signalling. Some of the diﬀerence observed in the
two studies is likely to be due to the high levels of expression
that can be tolerated when stable HEK-293 cell lines are gen-
erated. TNFRSF1A expression is tightly regulated and is low
in ﬁbroblasts and leucocytes, the cell types we studied from
the TRAPS patient. In these cells, reduced TNFRSF1A signal-
ling was observed. Thus, when TNFRSF1A expression is lim-
ited, reduced signaling is observed. Interestingly, Todd et al. [8]
also show that mutant receptors are unable to bind TNFa,
suggesting another mechanism whereby signaling could be
inhibited.
Both studies demonstrate that the extracellular domain of
TNFRSF1A plays a role in cell localisation. Previous work
has shown that deletion of the intracellular domain increase
surface expression. However, our data shows that this does
not occur for C43S or T50M TNFRSF1A mutants. Thus,
mutation of the extracellular domain appears to be a dominant
factor in the regulation of expression. It is possible that forma-
tion of the trimeric receptor, through the pre-ligand-binding
assembly domain, is required for the traﬃcking of the mole-
cule, or retention at the surface. Alternatively, misfolding of
the receptor, caused by the disruption of disulﬁde bonds and
other secondary structural changes as a result of the muta-
tions, may be suﬃcient to inhibit membrane expression. While
protein overexpression itself can lead to misfolding [8,18],
overexpression on its own cannot explain the diﬀerences in
staining patterns seen in this study, as WT TNFRSF1A was
expressed at higher levels than the TRAPS mutants, but could
still be detected on the cell surface of transfected cells. It is
likely that the TRAPS-associated mutations themselves are
inducing structural changes preventing receptor translocation
to the cell surface.
Our previous study, using TRAPS patient ﬁbroblasts, bear-
ing the C43S mutation, showed reduced NF-jB activation and
apoptosis, while cytokine production was normal [6]. Our tran-
sient transfection studies, in this paper, do not address all these
issues, but rather characterise NF-jB activation for a variety
5198 S. Siebert et al. / FEBS Letters 579 (2005) 5193–5198of TRAPS mutants. The decrease in NF-jB is seen when
receptors are expressed alone and in combination with wild
type receptor. Taken together, this suggests that loss of speciﬁc
TNFRSF1A signals is likely to be a general feature of TRAPS
phenotype.
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